We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome.
- Authors
Andrea J. Cussons; Gerald F. Watts; Valerie Burke; Jonathan E. Shaw; Paul Z. Zimmet; Bronwyn G.A. Stuckey
- Abstract
BACKGROUND Polycystic ovary syndrome (PCOS) is associated with insulin resistance and features in common with the metabolic syndrome (MetS)—factors shown to predict cardiovascular risk and type 2 diabetes. We investigated the prevalence and characteristics of the MetS in PCOS by three definitions—World Health Organization (WHO), National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP-III) and International Diabetes Federation (IDF)—and compared that with the background population. METHODS Cross-sectional study of 168 women with PCOS and 883 age-matched controls from the Australian Diabetes, Obesity and Lifestyle (AusDiab) study. RESULTS Prevalence of the MetS in PCOS subjects was 33% by WHO, 37% by NCEP-ATP-III and 40% by IDF criteria, compared with 10% by NCEP-ATP-III and 13% by IDF in controls (P P = 0.027) in obese women (BMI > 30 kg/m2), and higher but not significantly so in overweight (BMI 25–30 kg/m2) women (P = 0.052). Dehydroepiandrosterone sulphate was associated with a lower risk of the MetS—Odds ratio 0.86 (95% confidence interval, 0.77–0.97, P = 0.011). CONCLUSIONS An approximate 4-fold increase in the prevalence of the MetS in women with PCOS compared with the general population, consistent with the proposed major role of insulin and obesity in the syndrome, implies greater risk of cardiometabolic disease in women with PCOS. However, this estimate is likely to vary according to PCOS definition, ethnicity and different aetiological pathways to PCOS.
- Publication
Human Reproduction, 2008, Vol 23, Issue 10, p2352
- ISSN
0268-1161
- Publication type
Academic Journal
- DOI
10.1093/humrep/den263